doi:10.1152/ajpheart.00995.2008
You might find this additional information useful...
170 articles, 105 of which you can access free at: This article cites
http://ajpheart.physiology.org/cgi/content/full/296/1/H1#BIBL 2 other HighWire hosted articles: This article has been cited by
[PDF] [Full Text] [Abstract] , July 1, 2009; 297 (1): H21-H28.
Am J Physiol Heart Circ Physiol
L. Ao, N. Zou, J. C. Cleveland Jr., D. A. Fullerton and X. Meng
ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70 Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial
[PDF] [Full Text] [Abstract] , July 15, 2009; 83 (2): 277-284. Cardiovasc Res
P. Sicard, S. Jacquet, K. S. Kobayashi, R. A. Flavell and M. S. Marber
and TAK1
Pharmacological postconditioning effect of muramyl dipeptide is mediated through RIP2
including high-resolution figures, can be found at: Updated information and services
http://ajpheart.physiology.org/cgi/content/full/296/1/H1
can be found at: AJP - Heart and Circulatory Physiology
about Additional material and information
http://www.the-aps.org/publications/ajpheart
This information is current as of July 31, 2009 .
Physiological Society, 9650 Rockville Pike, Bethesda MD 20814-3991. Copyright © 2005 by the American Physiological Society. intact animal to the cellular, subcellular, and molecular levels. It is published 12 times a year (monthly) by the American
lymphatics, including experimental and theoretical studies of cardiovascular function at all levels of organization ranging from the publishes original investigations on the physiology of the heart, blood vessels, and
AJP - Heart and Circulatory Physiology
on July 31, 2009
ajpheart.physiology.org
Toll-like receptor signaling: a critical modulator of cell survival and ischemic
injury in the heart
Wei Chao
Anesthesia Center for Critical Care Research, Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
Submitted 13 September 2008; accepted in final form 5 November 2008
Chao W. Toll-like receptor signaling: a critical modulator of cell survival and
ischemic injury in the heart. Am J Physiol Heart Circ Physiol 296: H1–H12, 2009. First published November 14, 2008; doi:10.1152/ajpheart.00995.2008.—Toll-like receptors (TLRs) represent the first line of host defense against microbial infection and play a pivotal role in both innate and adaptive immunity. TLRs recognize invading pathogens through molecular pattern recognition, transduce signals via distinct intracellular pathways involving a unique set of adaptor proteins and kinases, and ultimately lead to the activation of transcription factors and inflam-matory responses. Among 10 TLRs identified in humans, at least two exist in the heart, i.e., TLR2 and TLR4. In addition to the critical role of these in mediating cardiac dysfunction in septic conditions, emerging evidence suggests that the TLRs can also recognize endogenous ligands and may play an important role in modu-lating cardiomyocyte survival and in ischemic myocardial injury. In animal models of ischemia-reperfusion injury or in hypoxic cardiomyocytes in vitro, the admin-istration of a sublethal dose of lipopolysaccharide, which signals through TLR4, reduces subsequent myocardial infarction, improves cardiac functions, and atten-uates cardiomyocyte apoptosis. By contrast, a systemic deficiency of TLR2, TLR4, or myeloid differentiation primary-response gene 88, an adaptor critical for all TLR signaling, except TLR3, leads to an attenuated myocardial inflammation, a smaller infarction size, a better preserved ventricular function, and a reduced ventricular remodeling after ischemic injury. These loss-of-function studies suggest that both TLRs contribute to myocardial inflammation and ischemic injury in the heart although the exact contribution of cardiac (vs. circulatory cell) TLRs remains to be defined. These recent studies demonstrate an emerging role for TLRs as a critical modulator in both cell survival and tissue injury in the heart.
apoptosis; cardiomyocytes; inflammation; innate immune; interleukin-1 receptor-associated kinase; ischemia-reperfusion; myeloid differentiation primary-response gene 88 adapter-like protein; myocardial infarction; nuclear factor-B; remodeling
INNATE IMMUNE SYSTEMS such as those mediated via Toll-like receptors (TLRs) represent the first line of defense against invading microbial pathogens. These receptors play a critical role in both innate and adaptive immunity (1, 102, 141). There are at least 10 TLRs identified so far in humans, and they recognize and specifically bind to a variety of pathogenic agonists such as lipopeptide (via TLR2), double-stranded RNA (via TLR3), lipopolysaccharide (LPS) (via TLR4), flagellin (via TLR5), and deoxycytidylate-phosphate-deoxyguanylate DNA (via TLR9) by molecular pattern recognition (1, 73). The stimulation of these TLRs leads to, through their specific intracellular signaling pathways, the activation of various downstream transcription factors and the ultimate production of inflammatory cytokines in host immune cells. In addition to their pivotal role in host immune defense against invading pathogens, TLRs, demonstrated by emerging evidence from the past 5–10 years, appear capable of responding to stress and
modulating inflammation and tissue damage following nonin-fectious insults such as hypoxia and ischemia in various tissues (107), such as the lung (68), liver (121), brain (84, 144), and heart (28, 36, 118, 136, 149).
In mice, the heart expresses at least six receptors involved in TLR signaling, namely TLR2, TLR3, TLR4, TLR5, TLR7, and TLR9 (17). A pathogenic ligand stimulation of TLR2, TLR4, TLR5, and TLR9 can lead to the activation of the NF-B pathway and cardiomyocyte contractile dysfunction (17, 81, 169). The two most-studied TLRs in the heart are TLR2 and TLR4 (41, 79, 80, 109, 169). Animal studies have indicated that these receptors are in part responsible for cardiac dysfunction in certain pathological conditions characterized in either gram-negative or gram-positive bacterial infection, such as endotoxemia (79, 109), peptidoglycan-associated lipopro-tein (169), and staphylococcus aureus (80). In the absence of a pathogen, an insult induced by transient tissue hypoxia and ischemia can induce a dramatic innate immune response in the myocardium, which has an adverse impact on cardiac anatomy and function. Probably for this very reason, the role of TLR signaling in ischemic myocardial injury (and in other cardio-vascular diseases) has been intensely studied in both human Address for reprint requests and other correspondence: W. Chao, Dept. of
Anesthesia & Critical Care, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 (e-mail: wchao@partners.org).
on July 31, 2009
ajpheart.physiology.org
and animals (39). However, population-based studies designed to determine the impact of TLR4 polymorphism on the risk of myocardial infarction (MI) are so far inconclusive, and the data seem conflicting. Some studies suggest that individuals with the single nucleotide polymorphism of TLR4 Asp299Gly, who have an impaired host immune response toward LPS stimula-tion, have a lower risk of MI (9, 15, 54), whereas others suggest an increased (32) or the same level of risk (83) of MI in the polymorphism compared with the control population. In animal models of ischemic cardiac injury, the role of TLRs is incompletely defined. For example, the systemic administra-tion of a sublethal dose of LPS, which signals through TLR4, reduced the subsequent ischemic MI and improved cardiac functions both in vivo and in isolated hearts (13, 18, 89, 99, 106, 138, 155, 166, 167). The activation of TLR4-myeloid differentiation primary-response gene 88 (MyD88) signaling also protects cardiomyocytes against apoptosis (26, 170). By contrast, in the absence of systemic TLR4 stimulation, mice deficient for TLR4 exhibited a reduced myocardial inflamma-tion and infarcinflamma-tion compared with wild-type (WT) mice in an in vivo model of ischemia-reperfusion (I/R) injury, suggesting that TLR4 mediates ischemic injury in the heart (28, 118). These studies demonstrate an emerging role for TLRs as a critical modulator in both cell survival and tissue injury in the heart. This article reviews the experimental evidence that demonstrates 1) the role of TLR signaling in modulating cardiomyocyte apoptosis, 2) LPS preconditioning against ischemic myocardial injury, and 3) the emerging role of TLR signaling in ischemic myocardial injury as well as inflammation as demonstrated by the loss-of-function studies in mice.
Discovery of Toll and TLR
Toll, meaning “amazing” and “wonderful” in German, was first described by Christiane Nu¨sslein-Volhard and colleagues in 1985 when they were studying the genetic mechanisms that control early embryonic development in the fruit fly Drosoph-ila (4, 5). They discovered that DrosophDrosoph-ila females that lacked Toll gene activity produced dorsalized embryos, in which all embryonic cells behaved like the dorsal cells of the WT embryo. As a result, the Toll-deficient embryos lacked any dorsal-ventral polarity. Together with Edward B. Lewis and Eric Wieschaus, Nu¨sslein-Volhard won the Nobel Prize in Physiology or Medicine in 1995 for their discoveries concern-ing the genetic control of early embryonic development (http:// nobelprize.org/nobel_prizes/medicine/laureates/1995/). Ten years after Toll was discovered, investigators found that Toll also played an important role in Drosophila host immunity against bacteria and fungi (85). A fly deficient of Toll died quickly of bacterial or fungus infection. In 1997, a group of investigators led by P. Medzhitov and C. A. Janeway, Jr., discovered that a human homolog of the Drosophila Toll protein was a trans-membrane protein with an extracellular domain consisting of a leucine-rich repeat domain and cytoplasmic domain homolo-gous to the cytoplasmic domain of human interleukin-1 (IL-1) receptor (103). The expression of a constitutively active mutant of human Toll or Toll-like protein in the cell line activated the NF-B pathway and the expression of NF-B-mediated proin-flammatory cytokines IL-1, IL-6, and IL-8. Between 1998 and 1999, two groups of investigators independently found that mice with mutated Lps gene, either a missense point (Pro3 His,
C3H/HeJ strain) or null mutation (C57BL/10 ScCr strain), con-ferred a natural hyporesponsiveness to endotoxin (120, 123). Through targeted gene (Lps) disruption, Hoshino and col-leagues (55) generated TLR4-deficient mice that were resistant to LPS. These pioneering studies firmly established TLR4 as the receptor for LPS, a wall component of gram-negative bacteria.
TLR-Signaling Pathways
There are 10 TLRs identified in humans (12, 101). Upon binding to its specific ligand via pattern recognition, TLRs recruit and activate various downstream kinases such as IL-1 receptor-associated kinase (IRAK)-1, IRAK-4, and TNF recep-tor-associated factor (TRAF)-family member-associated NF-B activator-binding kinase 1 (TBK1) via a specific set of adaptors (Fig. 1). There are five Toll/IL-1 receptor (TIR) domain-containing adaptors, namely MyD88, MyD88 adaptor-like pro-tein (Mal), TIR-domain-containing adaptor propro-tein inducing IFN--mediated transcription factor (TRIF), TRIF-related adaptor molecule (TRAM), and a sterile ␣- and armadillo-motif-containing protein (SARM) (112). TLRs interact with their respective adaptor(s) via the homologous binding of their unique TIR domains present in both the receptors and the adaptor molecules. Based on the specific adaptors recruited to TLRs, TLR signaling can be divided to two general pathways, namely, MyD88- and Trif-dependent (or MyD88-independent) pathways. The two distinct signaling pathways lead to the production of proinflammatory cytokines and type 1 IFN, respectively (112). As illustrated in Fig. 1, all TLRs, with the exception of TLR3, signal through MyD88-dependent path-ways. In TLR2 (and TLR1 and TLR6) and TLR4 signaling, Mal is required for recruiting MyD88 to the receptors (37). By contrast, in TLR3 and TLR4 signaling, a MyD88-independent pathway is initiated and another adaptor, Trif, is proven critical (53, 162).
The first and best known TLR is TLR4 (55, 120, 123). For LPS recognition, three additional proteins are required, includ-ing LPS bindinclud-ing protein (161), CD14 (160), and MD-2 (135). TLR4 signals via the two distinct pathways, MyD88-dependent and Trif-dependent pathways (112). In MyD88-dependent path-way, activated TLR4 recruits downstream IRAKs through the adapter proteins Mal and MyD88. Following a cascade of kinase activation as described below, this pathway ultimately leads to the activation of NF-B and production of proinflam-matory cytokine such as TNF and ILs (Fig. 1). In Trif-dependent pathway, TLR4 signals through TRAM-Trif that results in TBK1 activation and a downstream stimulation of IRF3 and production of IFN (Fig. 1). In TLR2 signaling, TLR2 dimerizes with either TLR1 or TLR6. The heterodimers recruit and activate IRAK4/1 via a Mal/MyD88-dependent mecha-nism and ultimately lead to the induction of cytokines. TLR2 signaling does not induce a production of IFN (Fig. 1).
As stated above, MyD88 is one of the five TIR domain-containing adaptors in TLR signaling (112) and plays a critical role in the signaling of all TLRs except TLR3 (64, 104, 108) (Fig. 1). It was originally isolated as one of the 12 myeloid differentiation primary response genes (91). It has a NH2-terminal death domain (DD) and a COOH-NH2-terminal TIR do-main. MyD88 binds to the TLR complex via the TIR-TIR domains and in turn recruits the downstream kinase IRAKs via
on July 31, 2009
ajpheart.physiology.org
their DD-DD interaction. Like TLR4⫺/⫺ mice (55), MyD88⫺/⫺ mice (72) lack the ability to respond to LPS although MyD88-independent mechanisms in TLR4 signaling exist (53, 74, 162) (Fig. 1).
First described as a signal transducer for the proinflamma-tory cytokine IL-1 (20), IRAK-1 was later implicated in the signal transduction of other members of the TLR/IL-1R family. Four different IRAK-like molecules have been identified: two active kinases, IRAK-1 and IRAK-4, and two inactive kinases, IRAK-2 and IRAK-like molecule (IRAK-M) (63). All IRAKs are multidomain proteins, consisting of a conserved NH2-terminal DD and a central kinase domain (63). The DD is a protein interaction motif implicated in the binding of IRAKs to the upstream adaptor protein MyD88. The recruited IRAK-1 becomes phosphorylated by activated IRAK-4. Phosphorylated IRAK-1 binds to TRAF-6 (21, 158). The IRAK-1-TRAF-6 complex then activates transforming growth factor--activated protein kinase 1 (TAK1) through a process involving the cytosol translocation of TAK1- and two TAK1-binding pro-teins from membrane to cytosol and the ubiquitination of TRAF-6 (69, 140). Activated TAK1 then phosphorylates IKK-␣/ as well as JNK/p38 kinases, leading to the activation of NF-B and activator protein-1, respectively (153).
It is noteworthy that several other signaling molecules (not shown in Fig. 1) are involved in the feedback regulation of TLR signaling. These include IRAK-M (82), MyD88s (19, 65),
an alternative splice product of MyD88, and SARM (22). These negative regulators may play an important role in LPS tolerance, a transient state of LPS refractoriness after the initial, sublethal exposure to LPS. Several mechanisms, among others, have been proposed to be responsible for endotoxin tolerance, including 1) the downregulation of the surface ex-pression of TLR4 (111, 132); 2) the inhibition of TLR signal-ing by IRAK-M, which prevents the dissociation of IRAK-1/4 from MyD88 and the formation of IRAK-TRAF-6 complexes (82) and by MyD88s, which block IRAK-4 binding to MyD88, as the negative regulators of TLR signaling (19); and 3) SARM, an adaptor protein that specifically blocks TRIF-dependent and MyD88-independent NF-B activation and gene induc-tion (22).
TLR Signaling Modulates Cardiomyocyte Apoptosis
Functional relevance of apoptosis in cardiac diseases. Al-though ischemia with associated hypoxia is the main initial event leading to ischemic MI, the molecular mechanisms involved in the consequent cardiomyocyte death are not com-pletely defined and have been studied extensively. Several lines of evidence suggest that apoptosis, or programmed cell death, and the caspase proteases central to the apoptotic pro-cess could play a role in the pathogenesis of cardiac disease including ischemic myocardial injury. Cardiomyocyte apopto-Fig. 1. Toll-like receptor (TLR) signaling. All TLRs are transmembrane proteins with a large extra-cellular domain containing leucine-rich repeats and a unique cytoplasmic Toll/IL-1 receptor (TIR) domain. TLRs exist in dimmers, and all TLR family members, except TLR3, signal through the key adaptor myeloid differentiation primary-response gene 88 (MyD88) to recruit downstream interleukin (IL)-1 receptor-associated kinases (IRAKs). In some TLR signaling, such as TLR2 and TLR4, MyD88 adaptor-like protein (Mal) is required for recruiting MyD88 to their receptors, whereas in others, such as TLR5, TLR7, TLR9, and TLR11, Mal is not required. TLR1 and TLR2 or TLR2 and TLR6 form heterodimers that signal through Mal/MyD88. TLR3 signals through the adaptor TIR-domain-containing adaptor protein inducing interferon- (IFN-)-mediated transcription-factor (Trif), which recruits and activates TNF receptor-associated factor-family member-associated NF-B activator-binding kinase 1 (TBK1). In addition to Mal/MyD88-dependent pathway, TLR4 can also signal through a MyD88-independent pathway that activates TBK1 via Trif-related adaptor molecule (TRAM)-Trif-dependent mechanism. TLR5, TLR7/8, TLR9, and TLR11 use only MyD88 as its signaling adaptor. These kinases ultimately activate transcription factors such as nuclear factor-B (NF-B) and IFN regulatory factor (IRFs), which result in production of various proinflammatory cytokines such as tumor necrosis factor (TNF), ILs, and IFNs.
on July 31, 2009
ajpheart.physiology.org
sis has been found in the injured myocardium of patients who had died of MI (62, 116, 131) and in animal models of infarction (43, 71, 130). Cardiomyocyte apoptosis is particu-larly prominent in reperfusion injury (43) and mainly localized in the border zone of the histological infarction area and a few in remote noninfarcted myocardiums (131). In animal models, the transgenic cardiac expression and conditional activation of procaspase-8 led to a significant cardiac apoptosis and a lethal-dilated cardiomyopathy; both can be prevented by an admin-istration of a broad-spectrum caspase inhibitor (157). In a mouse model of chronic pressure overload, the conditional deletion of cardiac gp-130 cytokine receptor led to the rapid onset of dilated cardiomyopathy and a massive induction of cardiomyocyte apoptosis versus that in the control mice which exhibit compensatory hypertrophy, thus suggesting that cardio-myocyte apoptosis is a critical element in the transition be-tween compensatory cardiac hypertrophy and heart failure (52). In a rat model of I/R injury, an intravenous administration of benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone, a broad caspase inhibitor, resulted in a modest but significant reduction in infarct size (33.4%) and cardiomyocyte apoptosis (72.1%) (163), demonstrating a link between cardiomyocyte apoptosis and ischemic myocardial injury. In a similar model of I/R injury, the adenovirus-mediated gene expression of a constitu-tive acconstitu-tive Akt (PKB) or human insulin-like growth factor I was sufficient to attenuate cardiomyocyte apoptosis and reduce infarct size (23, 42, 97, 98). Moreover, the transgene expres-sion of the dominant-negative (dn) mutant of Fas-associated DD protein (FADD), an adaptor protein critical for the death receptor (DR) pathway of apoptosis, inhibited apoptosis of hypoxic cardiomyocytes and reduced MI after I/R injury (24, 25). Thus the modulation of at least some targets in the apoptotic signaling pathways appears capable of mediating a meaningful anatomic and functional rescue following pressure overload or I/R injury.
Signaling pathways of cardiomyocyte apoptosis. The execu-tion of apoptosis is a tightly regulated and energy-dependent process that requires specialized cellular machinery (7, 8, 45). The central component of this machinery is a proteolytic system involving a family of proteases called cystein aspartic acid-specific proteases (caspases) (147, 148). The biochemical and cellular hallmarks of apoptosis is characterized by nuclear and DNA fragmentation and condensation, membrane bleb-bing, and cellular shrinkage. Although a fully comprehensive model of apoptosis has not been assembled, two general pathways have been delineated (45, 139, 148, 165), namely, the intrinsic or mitochondrial pathway and the extrinsic or DR pathway. In the intrinsic pathway, apoptosis occurs when specific stimuli lead to mitochondrial release of cytochrome c. Cytochrome c binds apoptotic protease-activating factor-1 in the cytosol and induces its oligomerization and the subsequent recruitment and activation of procaspase-9. In the DR pathway, a ligand such as CD95L/Fas ligand binding to DR leads to the activation of caspase-8 through specific adaptor molecules such as FADD. Both caspase-8 and -9 can lead to the activation of caspase-3 and to ultimate cell death. The two pathways coexist in many circumstance (29, 30, 87) and in cardiomyo-cytes (14, 67, 93, 143, 159).
TLR signaling modulates cardiomyocyte apoptosis. TLR4.
TLR4 has been linked to both parallel proapoptotic and survival pathways. LPS induces apoptosis in endothelial cells (27) and
hepatocytes (49), whereas it has an antiapoptotic effect in monocytes (44, 94), neutrophils (156), macrophages (90), and cardiomyocytes (26, 170). In the cells protected by LPS treat-ment, the activation of TLR4 triggers the expression of cell survival and inflammatory genes via NF-B-dependent mech-anisms. In the heart, an early report indicated that prolonged LPS treatment in rats activated proapoptotic and survival pathways and induced very modest cardiomyocyte apoptosis (100). However, the low levels of apoptosis appeared insuffi-cient to account for the LPS-induced cardiomyocyte dysfunc-tion, and its significance is uncertain. The data from a septic animal model (cecal ligation and puncture) indicated a minimal level of apoptosis in the heart, whereas a significant level of apoptosis was found in lymphocytes and in parenchymal cells of ileum, colon, lung, and skeletal muscle (33). Autopsy studies from patients who died of sepsis revealed minor apoptotic cell death in the heart, whereas there was profound lymphocyte and gastrointestinal epithelial cell death (56 –58). In fact, a recent study indicated that an in vivo administration of LPS actually reduced myocardial apoptosis induced by I/R injury (48). Moreover, in cell types such as endothelial cells, the induction of LPS-induced apoptosis did not occur unless the production of endogenous survival proteins was blocked (10, 11), again suggesting a parallel survival pathways in these cells. In an in vitro model of apoptosis, recent studies have demonstrated that LPS leads to a time- and dose-dependent antiapoptotic effect and phosphorylation of Akt and ERK in isolated cardiomyocytes (26). Both TLR4 and its adaptor MyD88 seem to mediate the survival benefit in the LPS-treated cardiomyocytes (170). The LPS-induced antiapoptotic effect can be blocked by phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, MEK1 inhibitor, and by dnIKK-, suggesting that all three kinases, i.e., Akt, ERK, and IKK-, contribute to the LPS-induced survival effect in cardiomyocytes (26). More-over, TLR4 mediates a robust inducible nitric oxide (NO) synthase (iNOS) induction both in mouse hearts and in isolated cardiomyocytes subjected to LPS. In that study (170), the antiapoptotic effect of LPS was almost abolished in cardio-myocytes deficient of iNOS, suggesting that iNOS was essen-tial for the TLR4-induced antiapoptotic effect (26). It is unclear and of great interest as to how endogenous iNOS regulates, in response to TLR4 stimulation, apoptosis signaling. It is note-worthy that iNOS also appears essential for the other form of cardioprotection, i.e., ischemic preconditioning (47), and that NO, derived from NO donors, has been shown to inhibit caspase-3 activity through S-nitrosylation and to reduce cardio-myocyte apoptosis (92, 129). However, the role of endogenous iNOS-NO in response to TLR4 activation in regulating caspase activity in cardiomyocytes has yet to be determined.
TLR2.An early study indicated that the synthetic lipopeptide or Escherichia coli lipoprotein induced NF-B activation and apoptosis in 293 cells (human embryonic kidney cells) that were stably transfected with human TLR2 but not in parental 293 cells which did not express TLR2, suggesting that TLR2 mediated a proapoptosis signaling (2). TLR2 also induces apoptosis in a human acute monocyte leukemia cell line THP-1 and in epithelial cells (2, 3). By contrast, other investigators have suggested that TLR2 signaling mediates an antiapoptotic effect and a proinflammatory pathway in cardiomyocytes sub-jected to hydrogen peroxide (40). These investigators found that oxidative stress-induced cytotoxicity in neonatal rat
on July 31, 2009
ajpheart.physiology.org
diomyocytes was enhanced by blocking TLR2 signaling with a specific antagonistic antibody. The reason for the discrepancy is unclear but likely mutilfactorial. The final phenotypic out-come of TLR2 activation with respect to cell survival may well be dependent on cell types (cell lines vs. primary cultures) and the type of apoptosis models and agents used.
MYD88.In the transfected 293 cell line, the expression of high
levels of exogenous MyD88 mediated TLR2-induced apopto-sis, possible through FADD-caspase-8-dependent pathway (3). However, using a genetically engineered mice (MyD88⫺/⫺) and in an acute lung injury model, Jiang et al. (68) have recently demonstrated that MyD88 mediates an antiapoptotic signal in lung epithelial cells and plays a critical role in pulmonary tissue repair and inflammation during the bleomy-cin-induced lung injury. Similarly, MyD88 appears essential for TLR4-activated antiapoptotic signaling in mouse cardio-myocytes (170) and in macrophages (90). Moreover, the ade-novirus-mediated expression of MyD88 modulates TLR2-in-duced cytokine production in mouse cardiomyocytes (169) but is not sufficient to affect cardiomyocyte apoptosis in vitro. By contrast, others reported that an overexpression of dnMyD88 led to reduced cardiomyocyte apoptosis in an in vivo model of I/R injury (59).
Interestingly, myocardial IRAK-1, a kinase critical for TLR signaling, quickly becomes activated in response to ischemic injury (26). It is unclear, however, as to how the kinase activation is initiated upon myocardial ischemia and the bio-logical significance that it may confer. Importantly, transgene expression of IRAK-1, but not its kinase-deficient mutant, appears sufficient to protect cardiomyocytes against apoptosis in vitro (26).
LPS Preconditioning Against I/R Injury
Evidence from several lines of investigation suggests that the activation of systemic TLR4 by LPS protects myocardium against I/R injury (Table 1). In animal models of I/R injury (13, 18, 48, 88, 89, 99, 106, 138, 155, 166, 167), in both in vivo (13, 48, 99, 138, 155, 166, 167) and ex vivo (18, 88, 106), a prior systemic administration of a sublethal dose of LPS reduces subsequent MI and improved cardiac functions. For example, hearts isolated from rats pretreated with a low dose of LPS (0.5 mg/kg) 24 h before had a better preserved myocardial function after I/R compared with the saline-treated control hearts (18, 105). Similar cardiac protection in LPS-treated animals was
observed in vivo and in different animal models of I/R injury, such as rabbit (13, 99), rat (18, 88, 106, 138, 155, 166, 167), and mice (48). The cardioprotective effect of LPS usually occurs between 12–24 h after the administration of LPS and is abolished by cycloheximide (106), suggesting a mechanism involving the de novo synthesis of cardioprotective proteins. LPS administration induces a robust induction of iNOS in the heart (154, 170), a process mediated via TLR4 (170). Similar to ischemic preconditioning (16), the cardioprotection con-ferred by LPS seems to be mediated by iNOS (155) and by Akt (48). Ha and colleagues (48) recently demonstrated that the cardiac benefit of LPS against I/R injury was abolished by an intraperitoneal administration of a PI3-kinase inhibitor or in transgenic mice expressing the inactive Akt mutant. These data suggest that LPS exhibits its cardioprotection via PI3-kinase/ Akt pathway and appear to be consistent with the in vitro observation that Akt, among other survival pathways, mediates a TLR4-mediated antiapoptotic benefit (26, 170). The afore-mentioned studies are important since they demonstrated a clear link between the activation of systemic TLR4 innate immune system and cardioprotection against ischemic myocar-dial injury and are consistent with the in vitro findings in isolated cardiomyocytes that demonstrate the antiapoptotic property of TLR4 signaling. However, given the multiple systemic responses following an in vivo administration of LPS, it is unclear whether the observed cardiac benefits are the direct results of TLR4 signaling or due to other events secondary to systemic TLR4 activation. Therefore, the critical role of TLR4, particularly that of cardiac origin, in the cardioprotection in vivo remains to be defined.
TLR Signaling Mediates Myocardial I/R Injury
Innate immune response during myocardial I/R. The innate immune response to I/R is, by far, the most common cause of myocardial inflammation. Acute inflammation is a complex response of soluble and cellular factors that together serve as the effector mechanisms of innate immunity. Molecular and cellular mechanisms underlying I/R injury are complex (164), involving the activation of endothelial cells and complement, an increased vascular permeability, and a rapid accumulation of neutrophils (38, 110, 119). Several hours after the onset of myocardial reperfusion, neutrophils accumulate in the in-farcted myocardial tissue in response to the release of chemoat-tractants: reactive oxygen species (ROS), cytokines, and the
Table 1. LPS-induced preconditioning against ischemic myocardial injury
Cardiac I/R Models Species Effects on the Heart References
Ex vivo
I/R Rat Increased LVDP 18, 106
Increased⫾dP/dtmax
Neutrophil-mediated I/R Rat Increased LVDP 88
Increased⫾dP/dtmax
In vivo
Rat Reduced ventricular arrhythmias and infarct size 138 Rat Reduced infarct sizes; decreased cardiac troponin T 166, 167
Rat Reduced infarct sizes via iNOS induction 155
Rabbit Reduced infarct sizes 13, 99
Mouse Reduced infarct sizes via PI3-kinase/Akt 48
I/R, ischemia-reperfusion; LVDP, left ventricular (LV) developed pressure;⫹dP/dtmax, maximum first derivative of developed LV pressure; ⫺dP/dtmax,
minimum first derivative of developed LV pressure; iNOS, inducible nitric oxide synthase; PI3-kinase, phosphatidylinositol 3-kinase.
on July 31, 2009
ajpheart.physiology.org
activated complements. The upregulated cell-adhesion mole-cules (ICAM-1, VCAM-1, and P-selectin), likely mediated by NF-B activation (86) in response to myocardial ischemia, facilitate the migration of neutrophils into the myocardial tissue. Neutrophils mediate cardiomyocyte death by causing vascular plugging, releasing degradative enzymes, and ROS (152), which causes myocardial injury by inducing a mitochon-drial permeability transition pore opening and a subsequent ATP depletion and cell death (50). Although many of the downstream events leading to I/R injury as mentioned above have been identified, the proximal signaling mechanisms that control these critical events during I/R remain incompletely defined.
Inflammation contributes to I/R injury. Evidence from sev-eral lines of investigation suggests that inflammation is an important functional contributor to the pathogenesis of ische-mic myocardial injury. For example, in animal models, neu-trophil depletion with antibodies (128) or physical filtering (34, 61), as well as the inhibition of neutrophil adhesion with anti-CD18 monoclonal antibody (142), all substantially reduce injury after reperfusion. In addition, interventions targeted at a variety of specific inflammatory mediators have demonstrated benefits in I/R injury, including complement depletion (96) or lipoxygenase inhibitors (133), or antibodies to the proinflam-matory cytokine IL-1 (60). However, some anti-inflamproinflam-matory intervention, notably corticosteroids, have yielded disappoint-ing results and actually increased infarct size and its compli-cations (126). Interestingly, some investigators have suggested that inflammation may actually play a beneficial role in the healing process after infarction (77). It is likely that inflamma-tion may play multiple roles in injury and recovery after I/R injury. For example, early neutrophil infiltration may contrib-ute to injury but later, predominantly mononuclear leukocyte recruitment may represent an important part of the healing process.
It is noteworthy that I/R injury can also occur experimentally in isolated hearts perfused with crystalloid solutions lacking cellular blood components and other systemic contributors (51) (e.g., in Langendorff perfusion system), as well as in the heart perfused with whole blood (e.g., in vivo I/R injury models). The common feature under both conditions is the reintroduc-tion of molecular oxygen, which contributes to the producreintroduc-tion of oxygen free radicals that cause tissue injury. Under condi-tions of whole blood reperfusion, there is the added influence of inflammatory cells such as neutrophils, as well as other blood-borne components. In addition, whole blood reperfusion in vivo also involves the activation of the coagulation cascade and the formation of the thrombolic occlusion of vessels and heterogeneity in the distribution of blood flow within the area of risk.
TLRs mediate myocardial inflammation and injury during I/R. Frantz and colleagues (41) first documented that there was an enhanced TLR4 expression in remodeling murine myocardium remote from sites of ischemic injury and in heart tissue from patients with idiopathic dilated cardiomyopathy. What is un-clear, however, is the functional significance of TLR4 upregu-lation under the cardiac conditions. During the past five years, evidence has emerged that clearly indicates that in addition to its role in the host immunity against invading pathogens, TLR signaling may also play a critical role in modulating cell survival and tissue injury (or repair) in “noninfectious” injury
models in several organs, such as lung (68), liver (121), brain (84, 144), and heart (28, 118, 136, 149), although, to make things even more complicated, TLR signaling seems to have different roles in different injury models. Of note, all of these investigations have been carried out in mouse models where genetic modifications of target genes are readily avail-able. For example, in the bleomyocin-induced acute lung injury model (68), TLR2 and TLR4 seemed to mediate proinflamma-tory and prosurvival signaling. Hyaluronan, produced in re-sponse to the acute lung injury, induces a proinflammatory and an antiapoptotic effect in lung epithelial cells via both TLR2-and TLR4-MyD88-dependent mechanisms (68). Similarly, in a hyperoxic lung injury model, the lack of TLR4 led to an increase in lung injury, apoptosis, and mortality (168), whereas the induced, active TLR4 (CD4hTLR4) transgenic expression in the lung confers resistance to hyperoxia-induced pulmonary apoptosis (124). By contrast, mice with the inactive TLR4 mutant or genetically deficient for TLR4 (28, 75, 118), TLR2 (35), or MyD88 (36) or pretreated intravenously with a TLR4 antagonist (Eritoran) (134) exhibited reduced MI sizes compared with WT or vehicle-treated animals, respectively, suggesting that TLR2 and TLR4 signaling contributed to ischemic injury in the heart (Table 2). However, the in vivo studies may have been com-plicated by the systemic deficiency/inhibition of TLR signal-ing. The lack of TLR signaling in extra-cardiac sources such as inflammatory cells could have contributed to the reduction of myocardial inflammation and thus injury after I/R. Recent studies have supported the notion that TLR4 of the extra-cardiac source (i.e., bone marrow-derived hematopoietic cells) plays an important role in mediating cardiac dysfunction under certain pathological conditions (145). In fact, in all of these studies mentioned above, a systemic TLR deficiency also leads to a significant reduction in the level of myocardial inflamma-tion as measured by neutrophil recruitment, an NF- B-depen-dent expression of cytokines and chemokines, and a comple-ment deposition in the heart after I/R. Therefore, it seems possible that the reduction in myocardial inflammation may have contributed to reduced MI sizes in these TLR-deficient animals. Thus the exact role of cardiac (vs. bone marrow-derived inflammatory cell) TLRs in ischemic myocardial injury remains to be investigated.
One of the key questions with respect to the role of TLR signaling in myocardial I/R injury is if and how TLRs become activated in response to ischemia and reperfusion. The obser-vation that myocardial IRAK-1 quickly becomes activated following coronary artery ligation seems to suggest that TLRs (or IL-1) respond to ischemic insult, although the upstream signaling remains unclear (26). Over the past 10 years, using the cells derived from TLR2⫺/⫺or TLR4 mutant mice or cells transfected with TLRs, investigators have identified a numbers of endogenous mediators that induce proinflammatory cyto-kine production through TLR2- and/or TLR4-dependent man-ners (Table 3). For example, in addition to LPS, TLR4 recog-nizes heat shock proteins (Hsp-22, Hsp-60, and Hsp-70) (6, 31, 113, 127, 150, 151), fibrinogen (137), fibronectin containing repeat extra domain A (114), surfactant protein-A (46), and soluble heparan sulfate (70). TLR2 is known to recognize Hsp-60 and Hsp-70 (6, 150, 151) and hyaluronan (68). Some of these endogenous molecules such as Hsp-60 and Hsp-70 are produced in response to myocardial ischemia (78, 95) and confer potent antiapoptotic and cardioprotective effects in the
on July 31, 2009
ajpheart.physiology.org
heart (66, 68, 76, 115). It remains unclear, however, and would be of great importance to investigate whether or not TLRs mediate the cardiac benefit induced by these molecular chap-erons and how to reconcile these findings with the suggested role of TLRs in I/R injury in the aforementioned loss-of-function studies.
MyD88, a key adaptor, contributes to myocardial I/R injury. As illustrated in Fig. 1, MyD88 is a key adaptor protein that is critical for transducing signals from all TLR family members (64, 73, 104, 108), except TLR3, and IL-1 receptor family members. Recent studies, employing adenovirus-mediated transgene expression and genetically modified mice, have dem-onstrated that MyD88 may play an important role in the pathogenesis of I/R injury in the heart. When overexpressed in
the heart, dnMyD88 led to a reduction in MI size and apoptosis in a rat model of I/R injury (59). It is of interest that the transgene expression of dnMyD88 also led to a decrease in myocardial inflammation given the well-characterized host innate immune response to adenoviral vectors in the heart (122). In a mouse model of I/R injury, Feng and colleagues (36) recently found that mice deficient of MyD88 had a reduced neutrophil recruitment and attenuated cytokine/adhe-sion molecule production (keratinocyte chemoattractant, monocyte chemoattractant protein-1, and ICAM-1), smaller infarct sizes, and much better preserved ventricular function as demonstrated by serial transthoracic echocardiographic and invasive hemodynamic measurements. In an effort to deter-mine the potential impact of MyD88 deficiency in circulatory Table 2. TLR signaling modulates myocardial I/R injury and remodeling
Mice Infarct Models Effects in Knockout Mice References
TLR2⫺/⫺
I/R (30⬘ I/60 R⬘) Smaller infarct sizes, reduced neutrophil recruitment, reduced ROS and cytokines
35 Permanent coronary ligation Improved survival rate, attenuated remodeling,
but same infarct sizes at 4 wk
136 TLR4
C57 BL/10 ScCr C3H/HeJ
I/R (60⬘ I/24 h R) Smaller infarct sizes, reduced MPO activity and complement 3 deposition
118
C3H/HeJ I/R (60⬘ I/120⬘ R) Smaller infarct sizes, decreased cardiac expression of TNF, MCP-1, and ILs
28
C3H/HeJ I/R (60⬘ I/24 h R) Smaller infarct sizes, but no gain in LV function 75
WT with eritoran I/R (30⬘ I/120⬘ R) Smaller infarct sizes, reduced pJNK, reduced cytokine expression
134 C3H/HeJ Permanent coronary ligation Reduced LV remodeling, improved systolic
function, reduced cytokine expression
149 C57 BL/10 ScCr Permanent coronary ligation Improved LV function on day 6 after infarction,
improved survival rate, reduced LV remodeling and apoptosis at 4 wk.
125
MyD88⫺/⫺ I/R (30⬘ I/24 h R) Smaller infarct sizes, improved LV function, and attenuated cytokine expression and neutrophil recruitment
36
TLR, Toll-like receptor; ROS, reactive oxygen species; MPO, myeloperoxidase; MCP-1, monocyte chemoattractant protein-1; pJNK, phosphorylated JNK; MyD88, myeloid differentiation primary-response gene 88.
Table 3. TLRs and their endogenous ligands
TLRs Endogenous Ligands Cells End Points References
TLR2 Hsp-60 Fibroblasts P38, JNK1/2, ERK1/2, IKK 150
Hsp-70 HEK293 NF-B 6
Fibroblasts NF-B 151
Hyaluronan Macrophages MIP-2, TNF, KC 68
TLR4 Hsp-22 Macrophages IL-6 127
Hsp-60 Fibroblasts P38, JNK1/2, ERK1/2, IKK 150
Macrophages TNF, NO 113
Hsp-70 HEK293 NF-B 6
Fibroblasts NF-B 151
Macrophage TNF 31
Fibronectin (extra domain A) HEK293 NF-B 114
Fibrinogen Macrophages MCP-1 137
Hyaluronic acid (oligosaccharides) Dendritic cells TNF, pMAPK 146
NF-B
Heparan sulfate (polysaccharide) Dendritic cells DC maturation 70
Hyaluronan Macrophages MIP-2, TNF, KC 68
Lung surfactant protein A Macrophages NF-B activity 46
Ovary cells TNF, IL-10
Hsp, heat shock protein; KC, keratinocyte chemoattractant; NO, nitric oxide; MCP-1, monocyte chemoattractant protein-1; pMAPK, phosphorylated MAPK; DC, dendritic cell; MIP-2, macrophage inflammatory protein-2.
on July 31, 2009
ajpheart.physiology.org
components on cardiac injury associated with the in vivo model of I/R, they tested the impact of cardiac MyD88 defi-ciency on myocardial injury in isolated mouse hearts. Surpris-ingly, they found that in isolated hearts subjected to global I/R, MyD88 deficiency had no effect on MI and left ventricular (LV) function following I/R (36). This finding suggests that in an in vivo condition, MyD88 may play a pivotal role in mediating myocardial inflammation that is critical for I/R injury and is consistent with the hypothesis that the cardiac benefits observed in MyD88⫺/⫺ mice in vivo may require circulating blood components during I/R.
TLR signaling modulates LV remodeling after ische-mic injury. LV remodeling represents myocardial structural changes in the LV in response to chronic alterations in loading conditions and contribute to morbidity and mortality after ischemic injury (117). LV remodeling can be induced by either pressure overload or volume overload, which results in a concentric remodeling or an eccentric hypertrophy, respec-tively. After MI, a stretched and dilated infarcted tissue in-creases LV volume with a combined volume and pressure load on noninfarcted areas. In a permanent coronary artery ligation model, Shishido and colleagues (136) demonstrated that TLR2-deficient mice had less LV remodeling at 4 wk, im-proved LV function at 1 and 4 wk, and a significantly higher survival rate at 4 wk compared with WT mice (Table 2). The reduced LV remodeling was demonstrated by a decreased myocardial fibrosis in the noninfarcted areas, a reduced trans-forming growth factor-, a collagen type 1 mRNA expression, and small LV dimensions at end diastole. Interestingly, the infarct size (at 4 wk) and level of inflammation (at 3–7 days) were similar between the two groups of animals in this model of MI. It is noteworthy, however, that the investigators in that study did not measure the infarct sizes during the early stage (e.g., 24 – 48 h) of ischemic injury. Therefore, the possibility that a potential MI size reduction in TLR2⫺/⫺mice compared with WT mice may contribute to the attenuated myocardial remodeling in TLR2⫺/⫺ animals needs to be ruled out. In a similar model of postinfarction remodeling, TLR4 was found to modulate survival as well as LV remodeling after ischemic injury (125, 149). Although an enhanced JNK expression has been implicated as a possible intracellular mechanism for the attenuated LV remodeling in TLR4⫺/⫺ mice (125), the exact mechanisms as to how TLR2 and TLR4 signaling is initiated during myocardial ischemia and how they modulate subse-quent ventricular remodeling remain elusive.
Summary
During the past decade, emerging evidence has indicated that in addition to their critical role in host immunity against microbial infection, TLRs can also function as a sensor re-sponding to tissue stress such as hypoxia and ischemia and modulate cell survival and tissue injury. Several lines of investigation have demonstrated the importance of cardiomyo-cyte apoptosis in myocardial I/R injury. Existing data suggest that TLR2 and TLR4 may mediate both pro- and antiapoptotic signaling, and the final phenotypic outcome probably depends on the cell types and the model of apoptosis used, although recent studies, both in vitro and in vivo, appear to support the notion that a direct activation of TLR4 leads to an antiapoptotic signaling in cardiomyocytes. A large body of evidence in
several animal models demonstrates that LPS, at sublethal doses, has a preconditioning-like effect protecting the heart against subsequent I/R injury. However, given the multiple systemic reactions in response to an in vivo administration of LPS in these studies, it is unclear whether the observed cardiac benefits are the direct result of TLR4 stimulation or due to other events secondary to systemic TLR4 innate immune activation. Therefore, the critical role of TLR4, particularly that of cardiac origin, in the cardioprotection in vivo is still unclear. By contrast and somewhat paradoxically, studies from several laboratories using knockout mouse models suggest that TLR2, TLR4, and MyD88 may all contribute to myocardial inflammation and infarction after I/R. It is noteworthy, how-ever, that in these models, TLR and MyD88 deficiency are systemic and, therefore, the exact contribution of TLR signal-ing of cardiac (vs. circulatory) origin is unknown. Neverthe-less, the disparate findings illustrate the complexity and diffi-culties in defining the emerging role of TLRs as a critical modulator in both tissue inflammation and injury. Defining the role of innate immune signaling in ischemic myocardial injury may have important therapeutic implications.
GRANTS
This work was supported by the Foundation for Anesthesia Education and Research and American Society of Anesthesiologists, an American Heart Asso-ciation Grant 0755890T, The William Milton Foundation of Harvard University, and National Institutes of Health Grants HL-04336 and GM-080906.
REFERENCES
1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 783– 801, 2006.
2. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf
JD, Klimpel GR, Godowski P, Zychlinsky A. Cell activation and
apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285: 736 –739, 1999.
3. Aliprantis AO, Yang RB, Weiss DS, Godowski P, Zychlinsky A. The apoptotic signaling pathway activated by Toll-like receptor-2. EMBO J 19: 3325–3336, 2000.
4. Anderson KV, Bokla L, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 42: 791–798, 1985.
5. Anderson KV, Jurgens G, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: genetic studies on the role of the Toll gene product. Cell 42: 779 –789, 1985.
6. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, Stevenson
MA, Calderwood SK. Novel signal transduction pathway utilized by
extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol
Chem 277: 15028 –15034, 2002.
7. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy recep-tors. Curr Opin Cell Biol 11: 255–260, 1999.
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation.
Science 281: 1305–1308, 1998.
9. Balistreri CR, Candore G, Colonna-Romano G, Lio D, Caruso M,
Hoffmann E, Franceschi C, Caruso C. Role of Toll-like receptor 4 in
acute myocardial infarction and longevity. JAMA 292: 2339 –2340, 2004. 10. Bannerman DD, Tupper JC, Erwert RD, Winn RK, Harlan JM. Divergence of bacterial lipopolysaccharide pro-apoptotic signaling downstream of IRAK-1. J Biol Chem 277: 8048 – 8053, 2002. 11. Bannerman DD, Tupper JC, Ricketts WA, Bennett CF, Winn RK,
Harlan JM. A constitutive cytoprotective pathway protects endothelial
cells from lipopolysaccharide-induced apoptosis. J Biol Chem 276: 14924 –14932, 2001.
12. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr
Top Microbiol Immunol 270: 81–92, 2002.
13. Belosjorow S, Schulz R, Dorge H, Schade FU, Heusch G. Endotoxin and ischemic preconditioning: TNF-␣ concentration and myocardial infarct development in rabbits. Am J Physiol Heart Circ Physiol 277: H2470 –H2475, 1999.
on July 31, 2009
ajpheart.physiology.org
14. Bialik S, Cryns VL, Drincic A, Miyata S, Wollowick AL, Srinivasan
A, Kitsis RN. The mitochondrial apoptotic pathway is activated by
serum and glucose deprivation in cardiac myocytes. Circ Res 85: 403– 414, 1999.
15. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der
Wall EE, Reitsma PH, Kastelein JJ, Jukema JW. Variants of toll-like
receptor 4 modify the efficacy of statin therapy and the risk of cardio-vascular events. Circulation 107: 2416 –2421, 2003.
16. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol 292: H19 –H27, 2007. 17. Boyd JH, Mathur S, Wang Y, Bateman RM, Walley KR. Toll-like
receptor stimulation in cardiomyocytes decreases contractility and ini-tiates an NF-kappaB dependent inflammatory response. Cardiovasc Res 72: 384 –393, 2006.
18. Brown JM, Grosso MA, Terada LS, Whitman GJ, Banerjee A,
White CW, Harken AH, Repine JE. Endotoxin pretreatment increases
endogenous myocardial catalase activity and decreases ische-mia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci USA 86: 2516 –2520, 1989.
19. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 197: 263–268, 2003.
20. Cao Z, Henzel WJ, Gao X. IRAK: a kinase associated with the interleukin-1 receptor. Science 271: 1128 –1131, 1996.
21. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 383: 443– 446, 1996. 22. Carty M, Goodbody R, Schroder M, Stack J, Moynagh PN, Bowie
AG. The human adaptor SARM negatively regulates adaptor protein
TRIF-dependent Toll-like receptor signaling. Nat Immunol 7: 1074 – 1081, 2006.
23. Chao W, Matsui T, Novikov MS, Tao J, Li L, Liu H, Ahn Y,
Rosenzweig A. Strategic advantages of insulin-like growth factor-I
expression for cardioprotection. J Gene Med 5: 277–286, 2003. 24. Chao W, Shen Y, Li L, Rosenzweig A. Importance of FADD signaling
in serum deprivation- and hypoxia-induced cardiomyocyte apoptosis.
J Biol Chem 277: 31639 –31645, 2002.
25. Chao W, Shen Y, Novikov MS, Li L, Ahn Y, Rosenzweig A. Adeno-viral expression of dominant-negative FADD blocks cardiomyocyte apoptosis and reduces myocardial injury after transient ischemia (Ab-stract). Circulation 106: II–131, 2002.
26. Chao W, Shen Y, Zhu X, Zhao H, Novikov M, Schmidt U,
Rosenz-weig A. Lipopolysaccharide improves cardiomyocyte survival and
func-tion after serum deprivafunc-tion. J Biol Chem 280: 21997–22005, 2005. 27. Choi KB, Wong F, Harlan JM, Chaudhary PM, Hood L, Karsan A.
Lipopolysaccharide mediates endothelial apoptosis by a FADD-depen-dent pathway. J Biol Chem 273: 20185–20188, 1998.
28. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ,
Rothnie CL, Yada M, Pohlman TH, Verrier ED. Toll-like receptor 4
mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc
Surg 128: 170 –179, 2004.
29. Deng Y, Lin Y, Wu X. TRAIL-induced apoptosis requires Bax-depen-dent mitochondrial release of Smac/DIABLO. Genes Dev 16: 33– 45, 2002.
30. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115: 61–70, 2003. 31. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N,
Sellevold OF, Espevik T, Sundan A. Inflammatory response after open
heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 105: 685– 690, 2002.
32. Edfeldt K, Bennet AM, Eriksson P, Frostegard J, Wiman B, Hamsten
A, Hansson GK, de Faire U, Yan ZQ. Association of hypo-responsive
toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 25: 1447–1453, 2004.
33. enchHotchkiss RS, Swanson PE, Cobb JP, Jacobson A, Buchman
TG, Karl IE. Apoptosis in lymphoid and parenchymal cells during
sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care
Med 25: 1298 –1307, 1997.
34. Engler RL, Dahlgren MD, Morris DD, Peterson MA,
Schmid-Schon-bein GW. Role of leukocytes in response to acute myocardial ischemia
and reflow in dogs. Am J Physiol Heart Circ Physiol 251: H314 –H323, 1986.
35. Favre J, Musette P, Douin-Echinard V, Laude K, Henry JP, Arnal
JF, Thuillez C, Richard V. Toll-like receptors 2-deficient mice are
protected against postischemic coronary endothelial dysfunction.
Arte-rioscler Thromb Vasc Biol 27: 1064 –1071, 2007.
36. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, Thibault H,
Scherrer-Crosbie M, Schmidt U, Chao W. Innate immune adaptor
MyD88 mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. Am J Physiol Heart Circ Physiol 295: H1311–H1318, 2008.
37. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA,
Mansell AS, Brady G, Brint E, Dunne A, Gray P, Harte MT, McMurray D, Smith DE, Sims JE, Bird TA, O’Neill LA. Mal
(MyD88-adapter-like) is required for Toll-like receptor-4 signal trans-duction. Nature 413: 78 – 83, 2001.
38. Frangogiannis NG, Smith CW, Entman ML. The inflammatory re-sponse in myocardial infarction. Cardiovasc Res 53: 31– 47, 2002. 39. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like
receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 4: 444 – 454, 2007.
40. Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes. J Biol
Chem 276: 5197–5203, 2001.
41. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT,
Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and
failing myocardium. J Clin Invest 104: 271–280, 1999.
42. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ische-mia-reperfusion injury in mouse heart. Circulation 101: 660 – 667, 2000. 43. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin
Invest 94: 1621–1628, 1994.
44. Goyal A, Wang Y, Graham MM, Doseff AI, Bhatt NY, Marsh CB. Monocyte survival factors induce Akt activation and suppress caspase-3.
Am J Respir Cell Mol Biol 26: 224 –230, 2002.
45. Green DR, Reed JC. Mitochondria and apoptosis. Science 281: 1309 – 1312, 1998.
46. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M,
Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung
surfactant protein-A involves Toll-like receptor 4. J Immunol 168: 5989 –5992, 2002.
47. Guo Y, Jones WK, Xuan YT, Tang XL, Bao W, Wu WJ, Han H,
Laubach VE, Ping P, Yang Z, Qiu Y, Bolli R. The late phase of
ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc Natl Acad Sci USA 96: 11507–11512, 1999.
48. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley
J, Gao X, Browder W, Williams DL, Kao RL, Li C.
Lipopolysaccha-ride-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. Cardiovasc Res 78: 546 –553, 2008.
49. Hamada E, Nishida T, Uchiyama Y, Nakamura J, Isahara K, Kazuo
H, Huang TP, Momoi T, Ito T, Matsuda H. Activation of Kupffer cells
and caspase-3 involved in rat hepatocyte apoptosis induced by endotoxin.
J Hepatol 30: 807– 818, 1999.
50. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35: 339 –341, 2003.
51. Hearse DJ, Humphrey SM, Chain EB. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. J Mol Cell Cardiol 5: 395– 407, 1973.
52. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Muller W,
Chien KR. Loss of a gp130 cardiac muscle cell survival pathway is a
critical event in the onset of heart failure during biomechanical stress.
Cell 97: 189 –198, 1999.
53. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim SO, Goode J,
Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B.
Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424: 743–748, 2003.
54. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 15: 15–21, 2005.
55. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y,
Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient
mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162: 3749 –3752, 1999.
on July 31, 2009
ajpheart.physiology.org
56. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis.
N Engl J Med 348: 138 –150, 2003.
57. Hotchkiss RS, Schmieg RE Jr, Swanson PE, Freeman BD, Tinsley
KW, Cobb JP, Karl IE, Buchman TG. Rapid onset of intestinal
epithelial and lymphocyte apoptotic cell death in patients with trauma and shock. Crit Care Med 28: 3207–3217, 2000.
58. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP,
Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in
patients with sepsis, shock, and multiple organ dysfunction. Crit Care
Med 27: 1230 –1251, 1999.
59. Hua F, Ha T, Ma J, Gao X, Kelley J, Williams DL, Browder IW, Kao
RL, Li C. Blocking the MyD88-dependent pathway protects the
myo-cardium from ischemia/reperfusion injury in rat hearts. Biochem Biophys
Res Commun 338: 1118 –1125, 2005.
60. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki
A, Hara M, Miyamoto T, Touma M, Sasayama S. Neutralization of
interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 38: 1546 –1553, 2001.
61. Ito BR, Engler RL, del Balzo U. Role of cardiac mast cells in complement C5a-induced myocardial ischemia. Am J Physiol Heart Circ
Physiol 264: H1346 –H1354, 1993.
62. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura
M, Jie T, Ito K. DNA fragmentation of human infarcted myocardial cells
demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol 146: 1325–1331, 1995.
63. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol
Cell 11: 293–302, 2003.
64. Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 27: 474 – 482, 2002.
65. Janssens S, Burns K, Tschopp J, Beyaert R. Regulation of interleu-kin-1- and lipopolysaccharide-induced NF-kappaB activation by alterna-tive splicing of MyD88. Curr Biol 12: 467– 471, 2002.
66. Jayakumar J, Suzuki K, Sammut IA, Smolenski RT, Khan M, Latif
N, Abunasra H, Murtuza B, Amrani M, Yacoub MH. Heat shock
protein 70 gene transfection protects mitochondrial and ventricular func-tion against ischemia-reperfusion injury. Circulafunc-tion 104: I303–I307, 2001.
67. Jeremias I, Kupatt C, Martin-Villalba A, Habazettl H, Schenkel J,
Boekstegers P, Debatin KM. Involvement of CD95/Apo1/Fas in cell
death after myocardial ischemia. Circulation 102: 915–920, 2000. 68. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, Prestwich GD,
Mascarenhas MM, Garg HG, Quinn DA, Homer RJ, Goldstein DR, Bucala R, Lee PJ, Medzhitov R, Noble PW. Regulation of lung injury
and repair by Toll-like receptors and hyaluronan. Nat Med 11: 1173– 1179, 2005.
69. Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X. Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling com-plexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol 22: 7158 –7167, 2002. 70. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated
monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 168: 5233–5239, 2002.
71. Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH,
Kra-jewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic
myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74: 86 –107, 1996.
72. Kawai T, Adachi O, Ogawa T, Takeda K, Akira S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11: 115–122, 1999. 73. Kawai T, Akira S. TLR signaling. Cell Death Differ 13: 816 – 825, 2006. 74. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S,
Hoshino K, Akira S. Lipopolysaccharide stimulates the
MyD88-inde-pendent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J
Im-munol 167: 5887–5894, 2001.
75. Kim SC, Ghanem A, Stapel H, Tiemann K, Knuefermann P, Hoeft A,
Meyer R, Grohe C, Knowlton AA, Baumgarten G. Toll-like receptor
4 deficiency: smaller infarcts, but no gain in function. BMC Physiol 7: 5, 2007.
76. Kirchhoff SR, Gupta S, Knowlton AA. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation 105: 2899 –2904, 2002.
77. Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E. Mum-mification of the infarcted myocardium by high dose corticosteroids.
Circulation 57: 56 – 63, 1978.
78. Knowlton AA, Brecher P, Apstein CS. Rapid expression of heat shock protein in the rabbit after brief cardiac ischemia. J Clin Invest 87: 139 –147, 1991.
79. Knuefermann P, Nemoto S, Misra A, Nozaki N, Defreitas G, Goyert
SM, Carabello BA, Mann DL, Vallejo JG. CD14-deficient mice are
protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 106: 2608 –2615, 2002. 80. Knuefermann P, Sakata Y, Baker JS, Huang CH, Sekiguchi K,
Hardarson HS, Takeuchi O, Akira S, Vallejo JG. Toll-like receptor 2
mediates Staphylococcus aureus-induced myocardial dysfunction and cytokine production in the heart. Circulation 110: 3693–3698, 2004. 81. Knuefermann P, Schwederski M, Velten M, Krings P, Ehrentraut H,
Rudiger M, Boehm O, Fink K, Dreiner U, Grohe C, Hoeft A, Baumgarten G, Koch A, Zacharowski K, Meyer R. Bacterial DNA
induces myocardial inflammation and reduces cardiomyocyte contractil-ity: role of toll-like receptor 9. Cardiovasc Res 78: 26 –35, 2008. 82. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov
R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor
signaling. Cell 110: 191–202, 2002.
83. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 27: 2524 –2529, 2006. 84. Lehnardt S, Lehmann S, Kaul D, Tschimmel K, Hoffmann O, Cho S,
Krueger C, Nitsch R, Meisel A, Weber JR. Toll-like receptor 2
mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 190: 28 –33, 2007.
85. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973–983, 1996. 86. Li C, Browder W, Kao RL. Early activation of transcription factor NF-B during ischemia in perfused rat heart. Am J Physiol Heart Circ
Physiol 276: H543–H552, 1999.
87. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–501, 1998.
88. Lipton BP, Bautista AP, Delcarpio JB, McDonough KH. Effects of endotoxin on neutrophil-mediated I/R injury in isolated perfused rat hearts. Am J Physiol Heart Circ Physiol 280: H802–H811, 2001. 89. Lipton BP, Delcarpio JB, McDonough KH. Effects of endotoxin on
neutrophil-mediated ischemia/reperfusion injury in the rat heart in vivo.
Exp Biol Med (Maywood) 226: 320 –327, 2001.
90. Lombardo E, Alvarez-Barrientos A, Maroto B, Bosca L, Knaus
UG. TLR4-mediated survival of macrophages is MyD88 dependent
and requires TNF-alpha autocrine signalling. J Immunol 178: 3731– 3739, 2007.
91. Lord KA, Hoffman-Liebermann B, Liebermann DA. Nucleotide se-quence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 5: 1095–1097, 1990.
92. Maejima Y, Adachi S, Morikawa K, Ito H, Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 38: 163–174, 2005.
93. Malhotra R, Brosius FC 3rd. Glucose uptake and glycolysis reduce hypoxia-induced apoptosis in cultured neonatal rat cardiac myocytes.
J Biol Chem 274: 12567–12575, 1999.
94. Manna SK, Aggarwal BB. Lipopolysaccharide inhibits TNF-induced apoptosis: role of nuclear factor-kappaB activation and reactive oxygen intermediates. J Immunol 162: 1510 –1518, 1999.
95. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88: 1264 –1272, 1993.
96. Maroko PR, Carpenter CB, Chiariello M, Fishbein MC, Radvany P,
Knostman JD, Hale SL. Reduction by cobra venom factor of
myocar-dial necrosis after coronary artery occlusion. J Clin Invest 61: 661– 670, 1978.
97. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ,
Rosenzweig A. Adenoviral gene transfer of activated
phosphatidylino-sitol 3⬘-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100: 2373–2379, 1999.
on July 31, 2009
ajpheart.physiology.org
